Pirtobrutinib by Eli Lilly and Co for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pirtobrutinib overview

Pirtobrutinib (Jaypirca) is an anti-neoplastic agent. It is formulated as film coated tablets for oral route of administration. Jaypirca is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

LOXO-305 (RXC-005) is under development for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), non-Hodgkin lymphoma including mantle cell lymphoma, marginal zone lymphoma, Waldenstrom macroglobulinemia, B-cell chronic lymphocytic leukemia (CLL) relapsed/refractory chronic lymphocytic leukemia (CLL) in patients resistant to ibrutinib, follicular lymphoma, diffuse large B-cell lymphoma and relapsing multiple sclerosis. It is administered through oral and intravenous route. The drug candidate is a next generation reversible BTK inhibitor.It acts by targeting tyrosine protein kinase BTK. It is a new molecular entity (NME).

Eli Lilly and Co overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

For a complete picture of Pirtobrutinib’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.